“…Earlier efforts focused on therapeutic effects such as reduced restenosis, using 1) inorganic coatings, including diamond-like carbon (Airoldi et al, 2004), pyrolytic carbon (Danzi et al, 2004), titanium nitride oxide (Windecker et al, 2005), and carbide (Unverdorben et al, 2003); 2) gene-eluting coatings, incorporating mRNA, siRNA, miRNA, or plasmid DNA of therapeutic genes in the coating; (Feldman et al, 2000;Sharif et al, 2012;Wang et al, 2021) 3) cell-seeded stent, using endothelial cells or progenitor cells (Zhu et al, 2008;Shi et al, 2010;Jantzen et al, 2011;Raina et al, 2014). The inorganic coatings provided ineffective or inconclusive performance (e.g., restenosis rate), compared to uncoated BMS (Kim et al, 2005;Meireles et al, 2007;O'Brien and Carroll, 2009). The gene-eluting coatings, like DES, incorporate genes for therapeutic moiety, but offer a longer term efficacy and a wider variety of therapeutic strategies beyond suppressing cell proliferation for restenosis inhibition (Yang et al, 2013;Adeel and Sharif, 2016;Fishbein et al, 2017;Hytönen et al, 2018).…”